We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 30, 2021

Effectiveness of the mRNA BNT162b2 COVID-19 Vaccine Up to 6 Months

The Lancet


Additional Info

The Lancet
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Lancet 2021 Oct 16;398(10309)1407-1416, SY Tartof, JM Slezak, H Fischer, V Hong, BK Ackerson, ON Ranasinghe, TB Frankland, OA Ogun, JM Zamparo, S Gray, SR Valluri, K Pan, FJ Angulo, L Jodar, JM McLaughlin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading